To better characterize how DAC functionally immunosensitizes primary glioma cells to recognition by NY-ESO-1 TCR engineered CD8+ T cells, we co-cultured NY-ESO-1 TCR-T with primary DBTRG-05MG GBM cells treated with or without DAC. This evidence concerns the gene CD8A and central nervous system cancer.